Enovis (NYSE:ENOV) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Enovis to “Buy” from “Hold,” while broader analyst sentiment remains “Moderate Buy,” with 10 Buy, one Hold and one Sell rating. The average analyst price target is $40.38.
• Enovis shares opened at $19.54, near their 52-week low of $18.08 and below both the 50-day and 200-day moving averages. The company recently exceeded quarterly EPS and revenue estimates, reporting $0.90 EPS and $582.78 million in revenue.
• Company insiders bought shares worth approximately $470,519 over the past three months, including purchases by the CEO and another insider. Institutional investors own 98.45% of Enovis stock.

Enovis (NYSE:ENOV - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other equities analysts have also commented on the stock. Weiss Ratings raised shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 21st. Citizens Jmp decreased their price objective on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating for the company in a report on Wednesday, September 2nd. BMO Capital Markets set a $27.00 target price on shares of Enovis in a research note on Tuesday, September 1st. BTIG Research dropped their target price on shares of Enovis from $40.00 to $36.00 and set a "buy" rating on the stock in a report on Tuesday, September 1st. Finally, Citigroup reiterated a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $40.38.

Enovis Stock Performance

ENOV opened at $19.54 on Friday. The company has a market cap of $1.13 billion, a PE ratio of -1.01 and a beta of 1.31. The stock has a 50-day moving average of $25.25 and a 200-day moving average of $24.10. Enovis has a 52-week low of $18.08 and a 52-week high of $34.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the prior year, the firm posted $0.79 EPS. The firm's revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts forecast that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert acquired 2,660 shares of Enovis stock in a transaction dated Friday, September 4th. The stock was bought at an average cost of $18.80 per share, with a total value of $50,008.00. Following the completion of the transaction, the insider owned 63,898 shares of the company's stock, valued at $1,201,282.40. The trade was a 4.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Damien Mcdonald acquired 13,035 shares of the stock in a transaction dated Friday, September 4th. The stock was bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares of the company's stock, valued at $4,731,524.55. The trade was a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 24,293 shares of company stock valued at $470,519 over the last three months. 2.90% of the stock is owned by company insiders.

Institutional Trading of Enovis

A number of hedge funds have recently bought and sold shares of ENOV. AQR Capital Management LLC increased its holdings in shares of Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company's stock worth $2,363,000 after purchasing an additional 7,072 shares during the period. Goldman Sachs Group Inc. increased its stake in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company's stock valued at $10,226,000 after acquiring an additional 73,116 shares during the period. Empowered Funds LLC raised its holdings in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock valued at $249,000 after acquiring an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock valued at $40,000 after acquiring an additional 707 shares in the last quarter. Finally, Amundi lifted its position in shares of Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company's stock worth $328,000 after acquiring an additional 9,762 shares during the period. 98.45% of the stock is owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.